Genetic Technology News

摘要

PDL Advances Mab Clinicals for Ulcerative Colitis; GTN Strategic Partners; Some Important Patents for You To Check; Technical Insights Launches Dnig Discovery Technology Alert and Energy & Power Systems Technology Alert. PROGENICS MONOCLONAL REDUCES HIV VIRAL LOAD: PRO 140, a monoclonal antibody being developed by Progenies Pharmaceuticals Inc. for treating human immunodeficiency virus (HIV) infection, showed a substantial reduction in viral load in a phase Ib clinical trial in infected patients. Individuals receiving a single 5.0 mg/kg maximum dose achieved an average maximum decrease of viral concentrations in the blood of 98.5%. Reductions in viral load of greater than 90% on average persisted for two to three weeks after dosing. The US Food andDrug Administration (FDA) has granted fast track status to the candidate. Progenies plans to start additional clinical testing in the second half of 2007.